All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, When would you favor haploidentical HSCT in ALL?
When would you favor haploidentical HSCT in ALL?
In this video, Nagler outlines the types of patients with acute lymphoblastic leukemia (ALL) who would benefit from haploidentical hematopoietic stem cell transplantation (HSCT) over unrelated and/or sibling donor transplantation.
Subscribe to get the best content related to ALL delivered to your inbox